Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

The maker of the FDA’s only approved total artificial heart has outlined plans to go public, with a $12 million IPO, ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on Thursday, April 3rd, IPO Scoop reports. The company will be issuing 2,700,000 shares at $7.50-$8.50 per share.

Though biotech IPOs have been quiet since 2021, industry experts believe that falling interest rates and favorable conditions for investments could reopen the IPO window for companies seeking ...

Though biotech IPOs have been quiet since 2021, industry experts believe that falling interest rates and favorable conditions for investments could reopen the IPO window for companies seeking ...

Endocrine-disease-focused Visen Pharmaceuticals is making its public market debut in Hong Kong, filing papers for an $86.5 ...

The biotech set aside a further 10% of its IPO haul for a planned trial of anti-CD24 antibody IMM47. ImmuneOnco revealed (PDF) a shift in its plan after the Hong Kong stock market closed Tuesday.

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Thursday, April 3rd, IPO Scoop reports. The company plans to issue 2,700,000 shares ...